NVM leads £1.9m investment in Altacor

The fresh funds will support Altacor's strategy to develop new and existing products for the global ophthalmology market. NVM believes this sector is currently showing strong growth prospects, driven by a number of factors such as an ageing population, improved eye screening and monitoring, an increase in laser eye surgery and the introduction of new treatments.

Founded in 2005, Altacor develops and markets drugs directed to the needs of both ophthalmologists and patients. The Cambridge-based company has a sales infrastructure that is active in the primary and secondary care sectors, as well as pharmacy and optical channels, through which its first product range for dry eye symptoms is being promoted.

The unquote" team is currently researching this transaction. In-depth deal information for subscribers will follow shortly.

If you have any information regarding this transaction, please contact Grégoire Gille on +44 20 7484 9824 or gregoire.gille@incisivemedia.com

 

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• UK / Ireland
• Expansion
• Healthcare
• NVM Private Equity